Navigation Links
Common Virus Enhances Cancer-Fighting Ability of Standard Chemotherapy Drugs

Can a common virus boost the cancer-killing abilities of existing cancer drugs? A preclinical study presented// at this year’s EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, in Prague, Czech Republic concluded that the answer is “yes.” These findings may lead to more effective treatment options for patients suffering from non-small cell lung cancer (NSCLC), a disease in which malignant (cancer) cells form in the tissues of the lung.

The research focused on work conducted by SAIC-Frederick, Inc., a prime contractor to the National Cancer Institute (NCI). The NCI tested the Respiratory Enteric Orphan virus, or reovirus, a non-disease causing virus in combination with a number of widely used chemotherapy drugs. In general, the combination of reovirus with cisplatin, gemcitabine, mitomycin or vinblastine was found to be more effective against NSCLC cell lines sensitive to anti-cancer drugs than each treatment used on its own. The study used REOLYSIN?, Oncolytics Biotech's proprietary formulation of the human reovirus, that has been demonstrated to replicate specifically in and kill tumor cells with activated Ras pathways (uncontrollable growth signals).

Of particular interest to the researchers, the combination of reovirus and paclitaxel, a common chemotherapy drug, was uniformly synergistic in all six cell lines examined, including in those with high-level resistance to paclitaxel or reovirus. The data suggest that the combination of reovirus and paclitaxel may help in promoting cell-death signaling, resulting in a more efficient and synergistic anti-cancer effect against these cell lines than using each agent on its own.

"Data from the NCI and other investigators examining various co-therapies with REOLYSIN is providing Oncolytics with the rationale for its planned combination clinical trial program," said Dr. Matt Coffey, the Chief Scientific Officer at Oncolytics. "This research suggests that REOLYSIN can be combined with many existing therapies that are currently broadly used in the treatment of cancer patients."

Currently, REOLYSIN is being used in Phase I and Phase I/II human clinical trials in the U.S. and the U.K. and the treatment has recently been approved for use in a Phase II trial in the U.K. for various advanced or metastatic cancers. The treatment appears to be well-tolerated by patients, and anti-tumor effects have been reported in all trials reported on to date. The Company plans to initiate human trials with REOLYSIN and various chemotherapies over the next year.

About 85% of all lung cancers are classified as the non-small cell type. Lung cancer is the leading cause of cancer death for both men and women. More people die of lung cancer than of colon, breast, and prostate cancers combined.

Source-Newswise
SM
'"/>




Related medicine news :

1. Common contraception
2. Common Cold Remedy May Treat SARS
3. Common Plant Triggers Asthma
4. Pain Common in People with MS
5. Common Cold Found to Fight Cancer
6. Bullying – a Common Problem Among Childre
7. Common Medication Errors in Children
8. A Common Cause Of Allergy That Goes Unnoticed
9. Genetic Breakthrough in Common Eye Problem
10. Common Cold Found to Fight Cancer Cells
11. Side Effects Of Some Common Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health ... Miles by Moonlight to raise money for the American Heart Association Heart Walk. Teams ... Teams will work together to keep their treadmills moving for 5 hours. Treadmills will ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer ... physician colleagues, skilled nursing facility medical directors and other clinicians at various events ... Care." , "At many of these conferences we get to educate other physicians, ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/7/2017)... IRVING, Texas , Oct. 6, 2017   ... industry with more than $100 billion in purchasing power, ... industry news and information. The Newsroom is ... chain and industry trends, infographics, expert bios, news releases, ... Besides having access to a wealth of resources at ...
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
Breaking Medicine Technology: